National Engineering Laboratory of Southwest Endangered Medicinal Resources Development, Guangxi Botanical Garden of Medicinal Plants, Nanning, 530023, PR China.
National Engineering Laboratory of Southwest Endangered Medicinal Resources Development, Guangxi Botanical Garden of Medicinal Plants, Nanning, 530023, PR China.
J Ethnopharmacol. 2021 May 10;271:113879. doi: 10.1016/j.jep.2021.113879. Epub 2021 Jan 30.
Sophora Tonkinensis Gagnep. (STG) has been used as a folk medicine for the treatment of different cancers, especially for nasopharyngeal carcinoma, cervical cancer, liver cancer, stomach cancer, lung cancer and leukemia in China. However, the main chemical composition and anticancer mechanism of chloroform extract of STG (CESTG) were still not very clear.
This work was carried out to investigate the anticancer effects and mechanisms of chloroform extract of STG (CESTG) on NPC.
Cultured NPC CNE1, CNE2 and Np69 cells were treated with CESTG. Cells were subjected to cell proliferation, colony-forming, migration and invasion assays. Cell cycle and apoptosis were measured by flow cytometry. Western blotting and morphological analysis were also performed. Tumor xenografts and drug treatments were made in BALB/c nude mice. The main compounds of CESTG was separated by HPLC.
CESTG inhibited cell viability, clonal growth and induced cell apoptosis in a dose-dependent manner by silencing the PI3K/AKT/mTOR signaling pathway, which is associated with upregulation of cleaved PARP, caspase 3/7/8/9, cleaved caspase 3/7/8/9, Bax and downregulation of PARP, P-PI3K, PI3K, P-AKT, AKT, P-mTOR, mTOR and Bcl-2. In addition, CESTG arrested cell cycle in the G1/S phase, correlating with decreased levels of cyclin D1/B1, CDK 4 and 6. CESTG decreased cell migration and invasion which correlated with decreased expression of β-catenin, vimentin and snail. CESTG significantly inhibited the tumor growth without toxicity.
The results presented here suggest that CESTG could be use as a potential source of NPC therapeutic drug.
中国民间医学一直用苦参(STG)治疗各种癌症,尤其是鼻咽癌、宫颈癌、肝癌、胃癌、肺癌和白血病。然而,苦参的氯仿提取物(CESTG)的主要化学成分和抗癌机制仍不是很清楚。
本研究旨在探讨苦参氯仿提取物(CESTG)对鼻咽癌的抗癌作用及其机制。
用 CESTG 处理培养的鼻咽癌 CNE1、CNE2 和 Np69 细胞。通过细胞增殖、集落形成、迁移和侵袭实验来检测细胞活力。通过流式细胞术检测细胞周期和凋亡。还进行了 Western blot 和形态分析。在 BALB/c 裸鼠中进行肿瘤异种移植和药物治疗。通过 HPLC 分离 CESTG 的主要化合物。
CESTG 通过沉默 PI3K/AKT/mTOR 信号通路,以剂量依赖的方式抑制细胞活力、克隆生长,并诱导细胞凋亡,这与 cleaved PARP、caspase 3/7/8/9、cleaved caspase 3/7/8/9、Bax 的上调和 PARP、P-PI3K、PI3K、P-AKT、AKT、P-mTOR、mTOR 和 Bcl-2 的下调有关。此外,CESTG 将细胞周期阻滞在 G1/S 期,与细胞周期蛋白 D1/B1、CDK 4 和 6 的水平降低有关。CESTG 降低细胞迁移和侵袭,这与β-catenin、波形蛋白和 snail 的表达降低有关。CESTG 显著抑制肿瘤生长而没有毒性。
本研究结果表明,CESTG 可作为治疗鼻咽癌的潜在药物来源。